Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is poised for success as a clinical-stage biotechnology company with a proprietary Native Complex Platform that has the potential to unlock the full potential of GPCR therapies. With a pipeline of product candidates focused on three therapeutic areas and upcoming clinical data release in the first half of 2026, Septerna is set to make a significant impact in the biotech industry. Additionally, the recent increase in price target to $35 reflects the company's strong financials and optimistic outlook.

Bears say

Septerna is making progress in its preclinical-stage development and has several programs in its pipeline, but has yet to identify a lead candidate for its TSHR NAM program. While the company has a partnership with Novo Nordisk, the financials and prospects seem risky and uncertain, with a conservative estimated price objective of $35 per share. Delays in clinical development and setbacks in trials, as well as potential approval and market penetration issues, pose additional risks for the company's success.

Septerna Inc (SEPN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.